Quarterly Updates6 Feb 2026, 02:10 pm
Solara Active Pharma Sciences Q3'26 Financial Results: Growth APIs Yield Results, Ibuprofen Business to be Evaluated
AI Summary
Solara Active Pharma Sciences Limited has announced its Q3'26 financial results. The company's growth APIs are showing strong performance, validating the strategic shift away from commodity-driven Ibuprofen base. The Board is appointing strategic advisors to evaluate options for the Ibuprofen business and re-assess the previously announced scheme for the CRAMS & Polymers business split. The growth API margin profile is now among the top in India, while the Ibuprofen business faces persistent headwinds due to global oversupply.
Key Highlights
- Growth APIs yielding results, validating strategic shift
- Board appointing strategic advisors for Ibuprofen business
- Ibuprofen business faces persistent headwinds due to global oversupply
- Growth API margin profile among the top in India
- Comprehensive roadmap for Ibuprofen and CRAMS initiatives to be presented next quarter